Valve Futures
Valve Futures
I honestly think it's a race between all three of those choices and some other dark horses out there. There is really big money out there for whoever finally gets it right. The beauty is that we don't care which company wins, as long as
somebody does...
- I strongly suspect the non-warfarin (apologies to Al) mechanical is closest to becoming reality. If it doesn't quite make it this time, someone will come up with an even slicker, denser pyrolitic carbon that mimics Teflon's antistick properties with carbon's integrity.
- A new plastic compound, perhaps from the polyurethane family, may yet show up that has flexibility, longevity, and non-warfarin capabilities.
- My all-time favorite would be the Chia valve, where your own tissue is grown on a framework. This would be your own valve. If they can't make them to last in the high-pressure aortic position, then they should make them for pulmonary use in Ross Procedures, until a better all-around solution is found.
- I think tissue valve usable lifespans will max out at 25-30 years, and wind up a blind alley for permanency. For now, they can be great for those for whom they are appropriate. They may continue to be used in people over 60-65, due to availability and nonreactivity to other prescriptions older folks need to take, reasons why they are popular for older folks now.
- Percutaneous valves are on the move. I still haven't found out what they're made of, but there are several companies out there making them and into clinical trials, including Edwards. I assume that ACT is involved, as it seems unlikely tissue could be mounted on an expandable stent reliably and without harming its integrity.
These valves will continue to popularize. Insurance companies will push hard for it, as implantation costs are lower (or will be - currently these valves are incredibly expensive). Interventional cardiologists will push hard for it, because it will be a new, lucrative procedure for them. Standard cardiologists will push for it, because it is expected to be a safer procedure, particularly for the fragile elderly.
Right now, percutaneously-implanted valves are not nearly as robust as more conventionally implanted valves. However, these companies will be competing with each other to improve these products to the extent that they can enter and compete in the mainstream market. It is likely that they will eventually succeed. This is somewhat disturbing, because if it becomes cheap enough, it may well be made the standard of care, even if it is only marginally satisfactory.
Best wishes,